Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 940-417-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The registration substance was investigated for its repeated dose toxicity according to the OECD Guideline 422. Indications of hemolysis and metabolic adaptation were found. No significant toxic effect was found up to the dose of 750 mg/kg bw.
For the assessment of the chronic toxicity of the registration substance, the read-across approach was introduced. Based on the knowledge on the mode of action/kinetic profile/chronic toxicity of the read-across supporting substances, the hazard profile of the registrations substance after prolonged exposure was predicted to be comparable to that found in the OECD 422 study. No classification is assigned.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2011-11-09 to 2013-05-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Health Effects guidelines, OPPTS 870.3650, Combined repeated dose Toxicity study with the Reproduction/ developmental Toxicity
screening Test. EPA 712-C-00-368, July 2000.
Commission Regulation (EC) No. 440/2008, L 142, Annex Part B, May 30, 2008
‘OECD Series on principles of Good Laboratory Practice and compliance monitoring’ Document No 13 ENV/JM/MONO (2002) 9. - GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test System
Species/strain: Wistar rats, Crl: WI(Han) (Full Barrier)
Source: Charles River, 97633 Sulzfeld, Germany
Sex: male and female; the female animals were non-pregnant and nulliparous.
Age at the start of the treatment period: males: 9-10 weeks old, females: 8-9 weeks old.
Body weight at the allocation of the animals to the experimental groups: Females: 171 to 202 g, (mean: 186.50 g, ± 20%= 37.30 g)
Males: 237 to 285 g, (mean: 264.21 g, ± 20%= 52.84 g)
The animals were derived from a controlled full-barrier maintained breeding system (SPF). According to Art. 9.2, No. 7 of the German Act on Animal Welfare the animals were bred for experimental purposes.
Housing and Feeding Conditions
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3°C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice
- Free access to tap water, sulphur acidified to a pH of approximately 2.8 (drinking water, municipal residue control,
microbiological controls at regular intervals)
- The animals were kept individually in IVC cages (except during the mating period when one female will be paired with one male),
type III H, polysulphone cages on Altromin saw fibre bedding
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least 5 days) under laboratory conditions
Preparation of the Animals
Prior to the start of the treatment period a detailed clinical observation outside the home cage was made.
Before the first administration all animals used for the study were weighed and assigned to the experimental groups
with achieving a most homogenous variation in body weight throughout the groups of males and females. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- The test item was weighed into a tared plastic vial on a precision balance and was suspended by adding the required volume of corn oil and
further vortexing it for 2-3 minutes. Homogeneity of the test item in the vehicle was maintained by vortexing the prepared suspension
thoroughly before every dose administration. The test item formulation was prepared freshly on each administration day before the
administration procedure. The vehicle was used as control item.
The following doses were evaluated:
Control: 0 mg/kg bw
LD: 100 mg/kg bw
MD: 250 mg/kg bw
HD: 750 mg/kg bw
The highest dose level was chosen with the aim of inducing toxic effects, but no death or severe suffering.
Thereafter, a descending sequence of dose levels was selected with a view to demonstrate any dosage related response and NOAEL.
The doses were selected on the basis of data from a Dose Range Finding Study.
The animals in the control group were handled in an identical manner to the test group subjects and received the vehicle
using the same dose volume.
Dose volumes were adjusted individually based on weekly body weight measurements. The administration volume was 4 mL/kg body weight. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Each dosing concentration was analysed for nominal concentration and homogeneity of the test item in the vehicle at various intervals.
Stability analysis was performed on samples collected from the top and bottom dose levels.
Samples for the nominal concentration verification was taken in study week 1 (first week of pre mating period), study week 3 (first week of mating),
study week 5 (gestation) and study week 7 (gestation/lactation).
Samples for homogeneity were taken from the top, middle and bottom of the high dose and low dose preparation in study week 1 and 5.
Samples for stability analysis was taken from top and bottom dose level in study week 1 at 0 hr and 6 hrs.
All concentration samples were stored frozen (approximately -20°C) until the analysis was performed.
The dose formulation analysis was performed at GLP-certified contract laboratory IBACON GmbH, Arheilger Weg 17, D-64380 Rossdorf,
Germany. - Duration of treatment / exposure:
- The animals were treated with the test item formulation or vehicle on 7 days per week for a period of 54 days,
i.e. during 14 days of pre-mating and 14 days of mating in both males and females, during the gestation period and
up to post-natal day 3 in females. Males were dosed after the mating period until the minimum total dosing period of 28 days was completed. - No. of animals per sex per dose:
- 96 animals (12 females and 12 males /group) were included in the study.
- Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
Once before the first exposure, and once a week thereafter, detailed clinical observations were made in all animals outside the home cage in a standard arena. Multiple detailed behavioural observations were made in the week before the first treatment and during the last week of the treatment in 5 randomly selected males and on lactation days in 5 randomly selected females (only lactating females were evaluated) outside the home cage using a functional observational battery of tests.
BODY WEIGHT: Yes
- Time schedule for examinations: The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment period as well as at the end of the study. During pregnancy, females were weighed on gestation days (GD) 0, 7, 14 and 20 and within 24 hours of parturition (day 0 post-partum) as well as day 4 post-partum along with pups.
FOOD CONSUMPTION:
- Food consumption was measured weekly on the corresponding days of the body weight measurements after the beginning of the
dose administration. Food consumption was not measured during the mating period in males and females and the post-mating period in males.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: yes
HAEMATOLOGY: Yes
The haematological examinations (Haematocrit, haemoglobin, erythrocyte count, total and differential leucocyte count, platelet count and blood clotting time) were made in all males (Control and HD groups), six selected males (LD and MD groups) and six selected females from Control, LD, MD and
HD groups. Blood samples were taken from abdominal aorta as a part of the procedure for killing the animals.
CLINICAL CHEMISTRY: Yes
Clinical biochemistry determinations to investigate major toxic effects in tissues and, specifically, effects on kidney and liver were performed on blood samples obtained from all males (Control and HD groups), six selected males (LD and MD groups) and six selected females of each groups. Investigations of serum included sodium, potassium, glucose, total cholesterol, urea, creatinine, total protein and albumin, two enzymes indicative of hepatocellular effects (such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase).
URINALYSIS: Yes
Urinalysis was performed on the samples collected from six randomly selected males at the terminal sacrifice.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: in the week before the first treatment and during the last week of the treatment
- Dose groups that were examined: all
- Battery of functions tested: sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The males were sacrificed after the completion of the mating period (after a dosing period of 28 days) except half of the males in control and HD
groups, which were further kept for 14 days recovery post 28 days dose administration and then scheduled for necropsy. Females were subjected to necropsy on the respective post-natal day 4. Males and females were sacrificed using an anesthesia (e.g. ketamine/xylazin). The pups were killed by decapitation on post-natal day 4.
Dead pups and pups sacrificed on day 4 post-partum were carefully examined externally for gross abnormalities.
Non-pregnant females (animal no. 54, 60 and 95) were sacrificed on study day 26 from the day of sperm-positive vaginal smear as an evidence of
mating.
All animals were subjected to a detailed gross necropsy, which includes careful examination of the external surface of the body, all orifices and the
cranial, thoracic and abdominal cavities and their contents. Special attention was paid to the organs of the reproductive system.
The number of implantation sites and corpora lutea was recorded for each parental female at necropsy.
The reproductive organs of all adult animals were weighed. The wet weight of the organs (liver, kidneys, adrenals, testes, epididymides, prostate,
seminal vesicles and coagulating glands, ovaries, uterus with cervix, thymus, thyroid/parathyroid glands, spleen, brain, pituitary gland, heart))
of all males of control and high dose groups (including the animals subjected to recovery), six randomly selected males of low and mid dose groups and six randomly selected females from each group were recorded as soon as possible. Paired organs were weighed separately.
The following tissues (brain (cerebrum, cerebellum and pons), ovaries (females), spinal cord, uterus with cervix (females),
liver, vagina (females), kidneys, testes (males), adrenal glands, epididymides (males), stomach, prostate and seminal vesicles
with coagulating glands as a whole (males), small and large intestines (including Peyer´s patches), urinary bladder,
thymus, lymphnodes (mesentric and axillary), Thyroid, peripheral nerve (e.g. sciatic nerve) with skeletal muscle,
spleen, bone with bone marrow (sternum), lung and trachea pituitary gland, mammary glands, oesophagus, heart, gross lesions)
of the same selected animals from each group were preserved in 10% neutral buffered formalin except eyes, testes and epididymides
that were fixed in Modified Davidson’s Fixative for approximately 24 hours before they were transferred to 10% neutral buffered formalin.
HISTOPATHOLOGY: Yes
All organs and tissues listed were evaluated from all males of the control and high dose group assigned to main or recovery necropsy,
as well as from the following six randomly selected females from the control and high dose group (assigned to main necropsy):
Females Nos.: 51, 53, 55, 56, 58, 59, 85, 87, 89, 90, 92, 94.
In addition, liver, kidney, spleen and thyroid gland were also evaluated from the following six randomly selected males and females from the
low dose and medium dose groups: Males Nos.: 13, 15, 19, 21, 22, 24, 27, 28, 29, 32, 33, 36; Females Nos.: 63, 64, 66, 68, 71, 72, 73, 74, 75,
80, 81, 83.
Reproductive organs (ovary, uterus, cervix, vagina, testis, epididymis, prostate gland, seminal vesicle and coagulating gland) and
macroscopic changes were evaluated in all study animals.
For the testes, a detailed qualitative examination was made; taking into account the tubular stages of the spermatogenic cycle at evaluation of
additional hematoxylin-PAS (Periodic Acid Schiff) stained slides.
Histological processing of tissues to microscope slides was performed at the GLP-certified contract laboratory Propath UK Ltd.
(test site for tissue processing), Willow Court, Netherwood Road, Hereford HR2 6JU, England. Histopathological evaluation was
performed at the GLP-certified contract laboratory KALEIDIS – Consultancy in Histopathology (test site for histopathology),
6 rue du Gers, 68300 Saint-Louis, France. Blocking, embedding, cutting, H&E staining and scientific slide evaluation were
performed according to the corresponding SOP’s of the test sites. - Statistics:
- For statistical analysis one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test was carried out to reveal any differences between control- and test groups. The student-t test was used for the comparison of recovery control and recovery high dose groups.
These statistics were performed with GraphPad Prism V.5 software (p<0.05 was considered as statistical significant). - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 750 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Critical effects observed:
- not specified
- Conclusions:
- The repeated dose toxicity of the registration substance was investigated according to the OECD Guideline 422. The registration substance induced hemolysis at 750 mg/kg bw at 750 mg/kg bw and liver enlargement in dose-dependent manner in all treated animals. These findings were reversible and there was no indication of functional impairment of blood system and liver. The NOAEL of 750 mg/kg bw was obtained.
Based on the findings obtained in this study, no classification is assigned to the registration substance. - Executive summary:
The repeated dose toxicity of the registration substance was investigated according to the OECD Gudieline 422. Twelve males and females each were treated at doses of 0, 100, 250 and 750 mg/kg bw via gavage. The study included the investigation of the recovery effect in males.Six rats of control and 750 mg/kg bw groups were allowed to recover for 14 days.
At 750 mg/kg bw, the hematology values were altered in males. Together with histopathological findings of extramedullary hemopoiesis and golden-brown pigments in spleens, these findings were considered as indication of hemolysis. Due to the limited degree of the hematology changes and due to the observed reversibility, no adversity was assigned.
Further, liver enlargement was found in dose-dependent manner both for males and females, which were accompanied with slightly changed values of clinical biochemistry and histopathological findings of glycogen storage. As there was no indication of impairment of liver funtion and as comparable values for liver weight were obtained from the animals of the recovery group, the liver enlargement was interpreted as of adaptive nature.
The NOAEL of 750 mg/kg bw was obtained for both males and females.
Reference
Table 1. Body weight development [g] |
|||||
Observation Parameter |
Dose |
||||
Control |
100 mg/kg |
250 mg/kg |
750 mg/kg |
||
Males |
Initial weight |
299 ± 16 (n = 12) |
298 ± 15 (n = 12) |
296 ± 16 (n = 12) |
298 ± 16 (n = 12) |
After premating phase |
336 ± 23 (n = 12) |
339 ± 20 (n = 12) |
332 ± 26 (n = 12) |
325 ± 19 (n = 12) |
|
After mating phase |
361 ± 28 (n = 12) |
361 ± 26 (n = 12) |
356 ± 29 (n = 12) |
350 ± 22 (n = 12) |
|
After recovery phase
|
380 ± 40 (n = 6) |
- |
- |
359 ± 22 (n = 6) |
|
Females |
Initial weight |
190 ± 10 (n = 10) |
196± 8 (n = 12) |
196± 8 (n = 12) |
197± 8 (n = 11) |
After premating phase |
203± 9 (n = 10) |
211± 12 (n = 12) |
209± 7 (n = 12) |
206 ± 10 (n = 11) |
|
Gestation day 0 |
207± 8 (n = 10) |
216± 13 (n = 12) |
213± 9 (n = 12) |
213 ± 10 (n = 11) |
|
Gestation day 20 |
316± 10 (n = 10) |
320± 30 (n = 12) |
317± 22 (n = 12) |
312 ± 21 (n = 11) |
|
Lactation day 0 |
230± 12 (n = 10) |
247± 20 (n = 12) |
240± 18 (n = 12) |
240 ± 13 (n = 11) |
|
Lactation day 4 |
242± 11 (n = 10) |
259± 20 (n = 12) |
248± 15 (n = 12) |
250 ± 13 (n = 11) |
Table 2. Hematology |
||||||
Observation Parameter |
At the treatment termination (one day after last treatment) |
After 14 days of recovery |
||||
Control |
100 mg/kg |
250 mg/kg |
750 mg/kg |
Control |
750 mg/kg |
|
Males |
||||||
WBC [103/µL] |
4.66 ± 0.46 (n = 6) |
4.74 ± 0.73 (n = 6) |
5.47 ± 0.65 (n = 5) |
5.50 ± 1.33 (n = 5) |
4.82 ± 0.85 (n = 6) |
5.64 ± 1.25 (n = 6) |
RBC [106/µL]
|
9.02 ± 0.25 (n = 6) |
8.60 ± 0.34 (n = 6) |
8.10 ± 0.49 * (n = 5) |
8.00 ± 0.61 * (n = 5) |
8.82 ± 0.24 (n = 6) |
8.79 ± 0.42 (n = 6) |
HGB [g/dL]
|
15.72 ± 0.66 (n = 6) |
15.43 ± 0.27 (n = 6) |
14.78 ± 0.49 (n = 5) |
14.42 ± 1.03* (n = 5) |
15.38 ± 0.26 (n = 6) |
15.45 ± 0.55 (n = 6) |
HCT [%] |
45.87 ± 1.46 (n = 6) |
44.68 ± 1.29 (n = 6) |
42.60 ± 1.61 * (n = 5) |
42.00 ± 2.82 * (n = 5) |
45.42 ± 1.43 (n = 6) |
46.35 ± 2.88 (n = 6) |
MCV [fl] |
50.83 ± 0.45 (n = 6) |
52.03 ± 1.56 (n = 6) |
52.68± 1.34 (n = 5) |
52.56± 0.92 (n = 5) |
51.48 ± 1.41 (n = 6) |
52.75 ± 2.30 (n = 6) |
MCH [pg]
|
17.40 ± 0.28 (n = 6) |
17.98 ± 0.47 (n = 6) |
18.26 ± 0.73 * (n = 5) |
18.06 ± 0.23 (n = 5) |
17.47 ± 0.59 (n = 6) |
17.62 ± 0.43 (n = 6) |
MCHC [g/dL]
|
34.25 ± 0.40 (n = 6) |
34.60 ± 0.51 (n = 6) |
34.66 ± 0.52 (n = 5) |
34.32 ± 0.18 (n = 5) |
33.92 ± 0.91 (n = 6) |
33.40 ± 1.64 (n = 6) |
PLT [103/µL]
|
857 ± 46 (n = 6) |
802 ± 195 (n = 6) |
871 ± 90 (n = 5) |
961± 50 (n = 5) |
856 ± 124 (n = 6) |
854 ± 74 (n = 6) |
PT [sec]
|
17.20 ± 0.56 (n = 6) |
18.87 ± 7.67 (n = 6) |
15.78 ± 0.89 (n = 5) |
12.00 ± 0.44 (n = 5) |
16.72 ± 0.60 (n = 6) |
17.30 ± 0.72 (n = 6) |
aPTT [sec]
|
19.62 ± 5.38 (n = 6) |
26.57 ± 12.47 (n = 6) |
32.52 ± 18.66 (n = 5) |
51.52 ± 18.65 ** (n = 4) |
26.47 ± 8.91 (n = 6) |
39.58 ± 29.46 (n = 6) |
Females |
||||||
WBC [103/µL] |
3.66 ± 0.30 (n = 6) |
3.50 ± 1.19 (n = 6) |
3.06 ± 0.45 (n = 6) |
3.85 ± 0.60 (n = 6) |
- |
- |
RBC [106/µL]
|
6.51 ± 0.41 (n = 6) |
6.17 ± 0.55 (n = 6) |
6.45 ± 0.37 (n = 6) |
6.20 ± 0.35 (n = 6) |
- |
- |
HGB [g/dL]
|
12.42 ± 0.83 (n = 6) |
11.93 ± 0.65 (n = 6) |
12.48 ± 0.66 (n = 6) |
12.00 ± 0.56 (n = 6) |
- |
- |
HCT [%] |
37.12 ± 2.21 (n = 6) |
35.67 ± 2.13 (n = 6) |
36.70 ± 1.49 (n = 6) |
36.47 ± 0.87 (n = 6) |
- |
- |
MCV [fl] |
57.08 ± 1.21 (n = 6) |
58.02 ± 3.70 (n = 6) |
56.98 ± 1.64 (n = 6) |
58.95 ± 2.31 (n = 6) |
- |
- |
MCH [pg]
|
19.08 ± 0.55 (n = 6) |
19.40 ± 1.26 (n = 6) |
19.38 ± 0.57 (n = 6) |
19.37 ± 0.42 (n = 6) |
- |
- |
MCHC [g/dL]
|
33.43 ± 0.49 (n = 6) |
33.43 ± 0.66 (n = 6) |
34.02 ± 0.91 (n = 6) |
32.85 ± 0.92 (n = 6) |
- |
- |
PLT [103/µL]
|
1269 ± 179 (n = 6) |
1251± 149 (n = 6) |
1239 ± 85 (n = 6) |
1331 ± 186 (n = 6) |
- |
- |
PT [sec]
|
16.76 ± 0.46 (n = 5) |
16.62 ± 0.44 (n = 6) |
16.56 ± 0.85 (n = 5) |
17.05 ± 0.32 (n = 6) |
- |
- |
aPTT [sec]
|
24.61 ± 12.35 (n = 5) |
19.02 ± 4.81 (n = 5) |
29.66 ± 14.11 (n = 5) |
31.93 ± 10.37 (n = 6) |
- |
- |
Table 3. Clinical Biochemistry |
|||||||
Observation Parameter |
At the treatment termination (one day after last treatment) |
After 14 days of recovery |
|||||
Control |
100 mg/kg |
250 mg/kg |
750 mg/kg |
Control |
750 mg/kg |
||
Males |
|||||||
ASAT [IU/L] |
18.60± 5.17 (n = 6) |
26.07± 6.50 (n = 6) |
22.83± 6.19 (n = 6) |
20.60± 5.51 (n = 5) |
29.90 ± 5.32 (n = 6) |
32.30 ± 23.19 (n = 6) |
|
ALAT [IU/L] |
18.58± 2.15 (n = 6) |
24.52± 2.66* (n = 6) |
23.40± 2.97 (n = 6) |
24.62± 5.51* (n = 5) |
19.27 ± 3.26 (n = 6) |
35.02 ± 41.81 (n = 6) |
|
ALP [IU/L]
|
126.17± 27.69 (n = 6) |
194.50± 82.28 (n = 6) |
161.17± 27.20 (n = 6) |
142.75± 55.78* (n = 4) |
139.17 ± 35.27 (n = 6) |
133.83 ± 25.44 (n = 6) |
|
GLU [mmol/L] |
16.99 ± 1.82 (n = 6) |
14.50 ± 4.85 (n = 6) |
13.90 ± 1.08 * (n = 6) |
15.40 ± 3.61 * (n = 4) |
14.79 ± 2.97 (n = 6) |
16.40 ± 5.15 (n = 6) |
|
UREA [mmol/L] |
5.97 ± 0.67 (n = 6) |
6.17 ± 0.63 (n = 6) |
5.40± 0.67 (n = 6) |
5.49± 0.52 (n = 5) |
6.25 ± 0.46 (n = 6) |
6.11 ± 1.50 (n = 5) |
|
CREA [µmol/L] |
27.63 ± 9.05 (n = 6) |
25.14 ± 5.41 (n = 6) |
24.50 ± 3.0 (n = 5) |
27.24 ± 5.75 (n = 5) |
24.10 ± 6.07 (n = 6) |
25.65 ± 12.29 (n = 5) |
|
CHOL [mmol/L] |
0.62 ± 0.11 (n = 6) |
0.81 ± 0.11 * (n = 6) |
0.90 ± 0.16 * (n = 5) |
0.82 ± 0.09 * (n = 5) |
0.60 ± 0.16 (n = 6) |
0.74 ± 0.08 (n = 6) |
|
TP [g/L] |
43.63 ± 3.28 (n = 6) |
55.08 ± 1.66 * (n = 6) |
51.62 ±1.91 * (n = 6) |
48.30 ± 1.89 * (n = 5) |
56.82 ± 2.76 (n = 6) |
58.23 ± 4.77 (n = 6) |
|
Na [mmol/L] |
134.83 ± 3.54 (n = 6) |
139.33 ± 1.37 * (n = 6) |
140.80 ±1.48 * (n = 5) |
139.00 ± 1.73 * (n = 5) |
140.67 ± 1.97 (n = 6) |
141.50 ± 3.39 (n = 6) |
|
K [mmol/L] |
4.84 ± 0.53 (n = 5) |
4.50 ± 0.28 (n = 6) |
4.24 ± 0.18 (n = 5) |
4.75 ± 0.29 (n = 3) |
4.67 ± 0.51 (n = 6) |
5.74 ± 2.55 (n = 6) |
|
ALBB [g/L] |
32.12 ± 2.02 (n = 6) |
33.80 ± 1.10 (n = 6) |
33.22 ± 2.19 (n = 5) |
32.22 ±1.93 (n = 5) |
32.02 ± 1.27 (n = 6) |
32.48 ± 2.14 (n = 5) |
|
TBA [µmol/L] |
10.84 ± 3.31 (n = 5) |
30.27 ± 21.24 (n = 6) |
16.19 ± 2.52 (n = 5) |
13.46 ± 6.44 (n = 5) |
25.03 ± 12.03 (n = 6) |
14.84 ± 6.39 (n = 6) |
|
Females |
|||||||
ASAT [IU/L] |
27.87 ± 7.27 (n = 6) |
32.57 ± 9.37 (n = 6) |
26.58 ± 5.07 (n = 6) |
31.28 ± 8.59 (n = 6) |
- |
- |
|
ALAT [IU/L] |
22.78 ± 6.29 (n = 6) |
22.93 ± 4.85 (n = 6) |
20.48 ± 5.67 (n = 6) |
27.43 ± 12.30 (n = 6) |
- |
- |
|
ALP [IU/L]
|
201.17 ± 120.65 (n = 6) |
194.83 ± 82.27 (n = 6) |
164.67 ± 71.03 (n = 6) |
157.17 ± 71.74 (n = 6) |
- |
- |
|
GLU [mmol/L] |
7.57 ± 1.40 (n = 6) |
7.66 ± 1.96 (n = 6) |
7.68 ± 1.70 (n = 6) |
7.48 ± 1.25 (n = 6) |
- |
- |
|
UREA [mmol/L] |
11.19 ± 1.28 (n = 6) |
12.07 ± 2.42 (n = 6) |
10.73 ± 1.47 (n = 6) |
11.39 ± 0.91 (n = 6) |
- |
- |
|
CREA [µmol/L] |
29.58 ± 4.41 (n = 5) |
24.80 ± 9.02 (n = 5) |
20.33 ± 4.12 (n = 5) |
27.07 ± 1.99 (n = 5) |
- |
- |
|
CHOL [mmol/L] |
0.73 ± 0.15 (n = 6) |
0.83 ± 0.07 (n = 6) |
0.81 ± 0.23 (n = 6) |
0.90 ± 0.23 (n = 6) |
- |
- |
|
TP [g/L] |
56.00 ± 3.66 (n = 6) |
58.00 ± 4.54 (n = 6) |
58.05 ± 4.91 (n = 6) |
56.70 ± 3.64 (n = 6) |
- |
- |
|
Na [mmol/L] |
144.83 ± 3.60 (n = 6) |
150.67 ± 6.02 (n = 6) |
148.00 ± 4.77 (n = 6) |
149.17 ± 6.68 (n = 6) |
- |
- |
|
K [mmol/L] |
4.83 ± 0.34 (n = 6) |
5.46 ± 0.85 (n = 6) |
4.99 ± 0.30 (n = 6) |
5.17 ± 0.35 (n = 6) |
- |
- |
|
ALBB [g/L] |
37.77 ± 2.81 (n = 6) |
38.13 ± 7.21 (n = 6) |
34.50 ± 7.56 (n = 6) |
38.25 ± 2.51 (n = 6) |
- |
- |
|
TBA [µmol/L] |
8.71 ± 8.73 (n = 6) |
8.70 ± 6.31 (n = 6) |
12.02 ± 7.11 (n = 6) |
14.59 ± 9.78 (n = 6) |
- |
- |
Table 4. Terminal body weight and liver weight [g] |
||||||
Observation Parameter |
At the treatment termination (one day after last treatment) |
After 14 days of recovery |
||||
Control |
100 mg/kg |
250 mg/kg |
750 mg/kg |
Control |
750 mg/kg |
|
Males |
||||||
Terminal Body weight [g] |
357 ± 18 (n = 6) |
366 ± 25 (n = 12) |
360 ± 31 (n = 12) |
357 ± 19 (n = 6) |
387 ± 40 (n = 6) |
371 ± 23 (n = 6) |
Liver weight [g] |
11.80 ± 0.78 (n = 6) |
13.12 ± 1.62 (n = 6) |
14.43 ± 2.44 * (n = 6) |
16.15± 1.60* (n = 6) |
13.17 ± 1.18 (n = 6) |
14.46 ± 1.59 (n = 6) |
Females |
||||||
Terminal Body weight [g] |
242 ± 11 (n = 10) |
259 ± 20 (n = 12) |
248 ± 15 (n = 12) |
250 ± 13 (n = 11) |
- |
- |
Liver weight [g] |
9.24 ± 0.74 (n = 6) |
11.17 ± 1.40 * (n = 6) |
11.56 ± 0.96 * (n = 6) |
13.31 ± 1.22 * (n = 6) |
- |
- |
|
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 750 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The repeated dose toxicity data comprise one subacute toxicity study (OECD 422) on the registrations substance and diverse studies on structurally related substances. The quality of whole database is considered to be sufficiently robust for a reliable hazard assessment on the registration substance.
Additional information
For the assessment of the chronic toxicity of the registration substance, the registration substance was grouped with structurally related chemicals. Following aspects will be discussed in the given order:
a) Justification for the applied read-across approach: basis for the grouping of chemicals
a1) Group members and the structural similarity
a2) Mode of action
a3) Comparable toxicity profiles after prolonged exposure
a4) Conclusion
b) The chronic toxicity of the registration substance based on grouping of chemicals
b1) Findings obtained in studies with DEGDBE, DEGBE, and EGBE
b2) Expected kinetic profile of the registration substance
b3) Expected toxicity after prolonged exposure based on the proposed read-across approach.
b4) Expected toxicity for humans based on the EU assessment on EGBE and DEGBE
b5) Conclusion
a) Justification for the applied read-across approach: basis for the grouping of chemicals
The applied read-across approach is based on grouping of chemicals, in which the same mode of action can be presumed.
a1) Group members and the structural similarity
The similarity in their structure is given by the presence of ”butyl-O-CH2CH2-O-“ at terminal position.
Grouping of chemicals for the hazard assessment of the registration substance |
||
Chemicals in read-across approach |
Chemical name/ CAS |
Structure |
Read-across supporting substances |
Ethylene glycol butyl ether (EGBE)* CAS 111-76-2 |
Butyl-O-CH2CH2-OH |
Diethylene glycol butyl ether (DEGBE)* CAS 112-34-5 |
Butyl-O-(CH2CH2-O)2-H |
|
Diethylene glycol dibutyl ether (DEGDBE)** CAS 112-73-2 |
Butyl-O- (CH2CH2-O)2-Butyl |
|
Registration substance/ target chemical |
Polyethylene glycol dibutyl ether (PolyEGDBE)*** CAS 31885-97-9 |
Butyl-O- (CH2CH2-O-)n-Butyl n = 2,3,4 |
* EGBE and DEGBE are extensively investigated substances and reviews on their toxicity profiles are available in public domain (i.e. EU Risk Assessment Report, 2-Butoxyethanol (EGBE), CAS 111 -76 -2, 2008; Opinion on Diethylene Glycol Monobutyl Ether (DEGBE), SCCP/1043/06, 2006). ** Clariant substance; relevant data provided in corresponding endpoint study record. *** registration substance; target chemical in the read-across.
a2) Mode of action
The proposed grouping is justified by the common mode of action, namely systemic exposure to 2-butoxyacetic acid (2-BAA) and/or butoxyethoxyacetic acid (BEAA):
- EGBE: 2-BAA is the major urinary metabolite (summarized in EU risk assessment, 2008)
- DEGBE: BEAA is the major urinary metabolite (Deisinger et al. 1989)
- DEGDBE: in 28-day study (Clariant own data; details provided in corresponding endpoint study record), the urinary 2-BAA determination was incorporated; 750 mg/kg bw external dose level corresponded to 1400 mg/L 2-BAA in urine.
- PolyEGDBE: no experimental data on metabolite is available; BEAA and/or 2-BAA as metabolite can be reasonably assumed due to the observed RBC reduction and liver enlargement in the OECD 422 study (Clariant own data; provided in corresponding endpoint study record).
a3) Comparable toxicity profiles after prolonged exposure
The proposed grouping is justified by the comparable toxicity profiles, which reflects the toxicity action of 2-BAA and/or BEAA. Both metabolites are known to induce hemolysis (Udden 2002; Udden 2005).
- EGBE: hemolytic action demonstrated in acute and repeated dose toxicity studies (summarized in EU risk assessment, 2008; selected studies provided in corresponding study record)
- DEGBE: i.e. in 2 and 13 week oral toxicity studies, RBC reduction was evident. (Johnson et al. 2005; provided in corresponding study record)
- DEGDBE: in 28-day study, RBC reduction and hematuria was evident (Clariant own data; provided in corresponding study record)
- PolyEGDBE: in OECD 422, RBC reduction was evident (Clariant own data; provided in corresponding study record)
a4) Conclusion: Based on a2) and a3), the introduced grouping is justified, which in turn justifies the use of the toxicity data of each group members for the hazard assessment of the registration substance.
b) The chronic toxicity of the registration substance based on grouping of chemicals
The toxicity data on the registration substance itself is limited to one subacute toxicity study (OECD 422). The treatment related effects found at 750 mg/kg bw were indicative of hemolysis. Because there was no indication of impairment of blood system and the reversibility after 14 days of recovery could be demonstrated, the dose level of 750 mg/kg bw was assigned as the NOAEL. In addition, the liver enlargement was found for all treated animals in dose-dependent manner. However, the liver effect was considered as signs of the metabolic adaptation and therefore, less relevant for the chronic toxicity.
b1) Findings obtained in studies with DEGDBE, DEGBE and EGBE
In all studies presented in this dossier, the red blood cell was identified as the target organ and the basis for the NOAELs was the adversity of hemolysis. By comparing the obtained NOAELs, a potency order of EGBE > DEGDBE > DEGBE ≈ registration substance can be obtained.
Table: Overview of the repeated dose toxicity studies of the grouped chemicals and NOAELs |
||
Group member |
Study type |
NOAEL /LOAEL |
Registration substance PolyEGDBE |
OECD 422 |
NOAEL of 750 mg/kg bw |
DEGBE |
13-week toxicity study |
NOAEL of 250 mg/kg bw |
DEGDBE |
28-day toxicity study |
NOAEL of 100 mg/kg bw |
EGBE |
14 week inhalation |
LOAEC of 31 ppm (150 mg/m3) |
104 week inhalation |
LOAEC of 31 ppm (150 mg/m3) |
* The mentioned studies are provided in corresponding study record
b2) Expected kinetic profile of the registration substance
The 28 -day study with DEGDBE comprised collection of urine samples after 8 and 28 days exposure and after recovery of 1 and 14 days (the endpoint study record provided under 7.1. in IUCLID). These samples were analyzed for the metabolite 2-butoxyacetic acid (2-BAA), which was found as the ultimate toxicant for the hemolysis (Udden 2002; Udden 2005). Comparable values were obtained in the samples of 8 and 28-day treatment and very low levels in the samples of recovery animals. These values are demonstrating that the steady state of the systemic exposure was already established within 8 days. Also the obtained very low levels in the recovery animals, especially already after one day of recovery, are indicating efficient elimination capacity. DEGDBE is a non-bioaccumulating substance, and likewise no significant bioaccumulating property can be assigned for the registration substance.
b3) Expected toxicity after prolonged exposure for the registration substance
Considering that:
- the overall data on the group members include up to the studies of 2 years
- the registration substance is of the lowest potency among the group members
- and no bioaccumulation can be soundly derived,
it is reasonable to consider the observed subacute toxicity of the registration substance as representative for subchronic/chronic toxicity. A low chronic toxicity can be derived.
b4) Expected toxicity for humans based on the EU assessment on EGBE and DEGBE
According to the official EU documents (EU Risk Assessment 2 -Butoxyethanol Cas 111 -76 -2, ECB, 2008; Opinion on Diethylene Glycol Monobutyl Ether (DEGBE) SCCP/1043/06, 2006) EGBE or DEGDBE are agents causing hemolysis in rats and mice. Humans are likely to be more resistent, so that toxic effects in such a degree found in animal studies cannot be expected. Based on the grouping of chemicals, it is justified to apply the same consideration also for the registration substance. The chronic toxicity of the registration substance for humans is expected to be low.
b5) Conclusion: Based on the provided arguments b1)-b4) the registration substance is considered as of low chronic toxicity.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Scientifically well-performed; Guideline study; GLP study; study on the registration substance
Justification for classification or non-classification
The registration substance was investigated for its repeated dose toxicity according to the OECD Guideline 422. Indications of hemolysis and metabolic adaptation were found. No significant toxic effect was found up to the dose of 750 mg/kg bw.
For the assessment of the chronic toxicity of the registration substance, the read-across approach was introduced. Based on the knowledge on the mode of action/kinetic profile/chronic toxicity of the read-across supporting substances, the hazard profile of the registrations substance after prolonged exposure was predicted to be comparable to that found in the OECD 422 study. No classification is assigned.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.